Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Mērķi: Abnormal Involuntary Movement Scale (AIMS)× | MDS-UPDRS× | |
|---|---|---|
| Nozare | Neiroloģija | Neiroloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1976 | 2008 |
| Autors≠ | National Institute of Mental Health | Christopher G. Goetz and Movement Disorder Society |
| Tips≠ | Clinician-rated observation | Clinician-rated |
| Pirmavots≠ | National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press. link ↗ | Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170. DOI ↗ |
| Citi nosaukumi | AIMS | UPDRS |
| Saistītās≠ | 3 | 5 |
| Kopsavilkums≠ | The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure. Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications. | The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice. |
| ScholarGateDatu kopa ↗ |
|
|